A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Darinaparsin (Primary)
- Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Solasia Pharma
- 08 Dec 2015 Pooled results (n=23) of this and other trial (see profile 206743) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 03 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.